December 20, 2025 01:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Horror in Bangladesh: Hindu man lynched and set on fire amid violent protests | Bangladesh in flames: Student leader Sharif Osman Hadi's death triggers massive protests, media offices torched | Chaos in Dhaka! Protesters assault New Age Editor, burn down newspaper offices amid deadly unrest | After campus shootings, Trump suspends green card lottery programme | ‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns
COVID-19
Image: PIB

Momentous feat: PM Modi after world's first DNA based anti-COVID-19 vaccine ZyCov-D gets nod

| @indiablooms | Aug 21, 2021, at 04:36 pm

New Delhi/IBNS: Prime Minister Narendra Modi has lauded the scientists after the world's first DNA based anti-COVID-19 vaccine, ZyCov-D, got approval for an emergency use in India.

The Prime Minister tweeted, "India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."

Zydus Cadila Friday received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.

Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.

This three-dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance.

The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.